The provided document is a security advisory from CISA regarding multiple vulnerabilities found in Fresenius Kabi's Agilia Connect Infusion System. It specifically mentions CVE-2021-43355 as one of these vulnerabilities.

Here's a breakdown of the relevant information regarding CVE-2021-43355:

**Root Cause of Vulnerability:**

*   The Vigilant MasterMed application performs user input validation on the client-side (using JavaScript) without proper server-side authentication.

**Weaknesses/Vulnerabilities Present:**

*   **Use of Client-side Authentication (CWE-603):** The server relies on client-side validation, which can be bypassed or disabled by malicious users. The server does not authenticate requests itself

**Impact of Exploitation:**

*   An attacker with knowledge of a service user can bypass client-side controls and log in with service privileges.
*   This could lead to unauthorized access to sensitive functionalities and data within the Vigilant MasterMed application.

**Attack Vectors:**

*   Network-based attack, as the vulnerability is exploited by sending crafted requests to the web application.

**Required Attacker Capabilities/Position:**

*   Network access to the Vigilant MasterMed application.
*   Knowledge of the service user credentials that the client-side authentication is attempting to validate.
*   The attacker does not need to be authenticated before performing the attack.